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Prion Protein Devoid of the Octapeptide
Repeat Region Restores Susceptibility
to Scrapie in PrP Knockout Mice
of PrP propagates by interacting with PrPC and con-
verting it into a likeness of itself (Prusiner, 1989, 1996;
Weissmann et al., 1996). It has been proposed that a
partially protease-resistant, aggregated form of PrP,
named PrPSc or PrP-res, is congruent with PrP*, mainly
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because purification of infectivity leads to enrichment of1 Institut fuÈ r Molekularbiologie
PrPSc and because both infectivity and PrPSc are largelyAbteilung I
resistant to proteinase K digestion (Prusiner, 1989).UniversitaÈ t ZuÈ rich However, in some instances, brains of animals or hu-
8057 ZuÈ rich mans suffering from prion disease are devoid of detect-2 Institut fuÈ r Neuropathologie able levels of protease-resistant PrP (Collinge et al.,
UniversitaÈ tsspital ZuÈ rich 1995; Telling et al., 1996; Lasmezas et al., 1997; Manu-
8091 ZuÈ rich elidis et al., 1997; Manson et al., 1999); the significance
Switzerland of this finding must be tempered by the consideration
that the detection limit for infectivity is three to five
orders of magnitude lower than for PrPSc.
One of the more remarkable features of human prionSummary
diseases is that they arise not only as a consequence
of transmission, but also of mutations in the PrP geneMice devoid of PrP are resistant to scrapie and fail to
(Hsiao et al., 1989; Collinge and Palmer, 1994; Parchireplicate the agent. Introduction of transgenes ex-
and Gambetti, 1995; Collinge, 1997; Prusiner and Scott,pressing PrP into such mice restores susceptibility to
1997). In addition to about 20 different point mutationsscrapie. We find that truncated PrP devoid of the five
associated with Creutzfeldt-Jakob disease (CJD), Gerst-copper binding octarepeats still sustains scrapie in-
mann-StraÈ ussler-Scheinker disease (GSS), and fatal fa-fection; however, incubation times are longer and
milial insomnia (FFI) in man, there are also amplifications
prion titers and protease-resistant PrP are about 30- of a stretch of octarepeats in the amino-proximal region
fold lower than in wild-type mice. Surprisingly, brains of PrP from normally 5 to as many as 14 (Krasemann et
of terminally ill animals show no histopathology typical al., 1995; Collinge, 1997), suggesting that this region of
for scrapie. However, in the spinal cord, infectivity, glio- PrP might be important for the spontaneous conversion
sis, and motor neuron loss are as in scrapie-infected event.
wild-type controls. Thus, while the region comprising Mice devoid of PrP develop and behave normally
the octarepeats is not essential for mediating patho- (BuÈ eler et al., 1992) but are resistant to prion disease
genesis and prion replication, it modulates the extent (BuÈ eler et al., 1993; Manson et al., 1994; Sailer et al.,
1994; Sakaguchi et al., 1995). Moreover, introduction ofof these events and of disease presentation.
PrP transgenes into such Prnpo/o mice restores suscepti-
bility to scrapie (Fischer et al., 1996), thus paving theIntroduction
way to structure±function analyses of PrP. In earlier ex-
periments, we showed that in Prnpo/o mice overexpres-PrP, the prion protein, plays a central role in the patho-
sion of truncated PrP transgenes encoding PrP with agenesis of transmissible spongiform encephalopathies
deletion of codons 32±80 (inclusive) and therefore re-such as scrapie or bovine spongiform encephalopathy
taining only one of the five octarepeats, sustained repli-(BSE) (Prusiner, 1996, 1998; Weissmann, 1999; Weiss-
cation of infectious agent and development of diseasemann et al., 1996). The normal form of PrP, designated
(Fischer et al., 1996).PrPC, is encoded by a single-copy gene (Basler et al.,
We now show that PrP with a deletion of codons 32±931986) and is expressed in the brain of healthy and prion-
(inclusive), and thus devoid of all five octarepeats, alsoinfected organisms to about the same extent (Chesebro
restores susceptibility to scrapie in PrP knockout mice.et al., 1985; Oesch et al., 1985). There is overwhelming
However, incubation times are longer and result in prion
evidence that a modified form of PrPC, which we desig- titers in brain and spleen that are lower than in wild-
nate as PrP* (Weissmann, 1991), is the principal if not type mice in all stages of the disease. Interestingly, even
the only component of the infectious agent, or prion in terminally ill mice, no histopathological changes were
and that it is devoid of nucleic acid. The ªprotein-onlyº evident in the brain at the level of light microscopy;
hypothesis (Griffith, 1967) states that the abnormal form however, there was neuronal loss and astrogliosis in the
cervical spinal cord. Thus, while the octarepeat se-
quence is not essential for sustaining prion replication3 To whom correspondence should be addressed (e-mail: c.
weissmann@ic.ac.uk). and disease, it does affect the level of prion accumula-
4 These authors contributed equally to this work. tion and pathogenesis in the brain.
5 Present address: Core Technologies Deptartment, Novartis Pharma
AG, 4002 Basel, Switzerland. Results
6 Present address: MRC Prion Unit/Neurogenetics, Imperial College
School of Medicine at St.Mary's, London W2 1PG, United Kingdom.
Generation and Characterization of PrP Knockout7 Present address: Department fuÈ r Innere Medizin, Abteilung fuÈ r In-
Mice Transgenic for PrP with a Deletionfektionskrankheiten, UniversitaÈ tsspital ZuÈ rich, ZuÈ rich 8091, Swit-
of Amino Acids 32±93zerland.
We prepared two mouse lines, C4/C4 and C15/C15,8 Present address: Department of Pathology, Stanford University
School of Medicine, Stanford, California 94304. expressing truncated PrP devoid of the five octarepeats
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Figure 1. Western Blot Analysis of Total, Phosphotungstate-Precipitable, and Protease-Resistant PrP
Samples from uninfected or RML-infected, terminally ill mice were analyzed by Western blotting before (A and B) or after phosphotungstate
(NaPTA) precipitation (C and D) as described in Experimental Procedures, using antisera 6H4 for PrP.
(A) Brain homogenates from uninfected mice; the blots were also stained with antibody 22C11 for APP, which served as internal control.
Quantification was as described in the Experimenal Procedures section.
(B) Brain homogenates from RML-infected, terminally ill mice without (2) and after (1) proteinase K treatment.
(C) Brain homogenates of noninoculated PrPo/o and C4/C4 mice or RML-infected, terminally ill wild-type and C4/C4 mice were subjected to
the NaPTA precipitation procedure. The pellets were resuspended in sample buffer with 8 M urea without prior protease treatment (2PK).
(D) Samples were prepared and analyzed as in (C), but pellets were resuspended in 0.1% Sarkosyl and treated with proteinase K (1PK) before
loading.
In both (C) and (D), aliquots of 22 ml (lanes marked 1) or the fraction thereof as indicated were subjected to Western blot analysis. Except for
the C15 mouse in (B), all mice were homozygous for the transgene.
(PrPD32±93) on a Prnpo/o background, using the ªhalf retaining only one octarepeat (tgd12/tgd12 [Fischer et
al., 1996]) (Figures 3A±3C and 3H±3J). Moreover, nogenomicº PrP vector in which the reading frame is under
control of the PrP promoter (Shmerling et al., 1998). Both alterations were found in skeletal muscle and peripheral
nerves (data not shown). However, strong astrogliosislines of mice, homozygous for the transgene cluster,
expressed the mutant protein in brain at about 4-fold and spongiosis were seen in the spinal cord of terminally
ill mice expressing PrPD32±93, as in wild-type PrP (Fig-higher level than wild type (Figure 1A; Table 1). The
distribution of the truncated PrP in brain and brainstem ure 4A). Moreover, there was a reduction in the number
of motor neurons in the Rexed laminae VIII and IX ofwas similar to that of full-length PrP in wild-type mice
(Figure 2A). Mice of both lines remained healthy without the spinal cord. In the cervical spinal cord levels C4±C8,
the motor neuron reduction of about 10%±25% in in-any neurological signs for over 800 days.
fected C4/C4 mice was similar to that of infected wild-
type and tga20/tga20 mice, as compared with age-Susceptibility to Mouse Prions of PrP Knockout
matched mock infected mice (Figure 4B). No significantMice Transgenic for PrPD32±93
loss of motor neurons was found in the thoracic (T1)About 200±300 days after intracerebral (i.c.) inocula-
and lumbar (L1±L4) spinal cord levels of infected micetion with mouse-adapted prions (Table 1), hemizygous
of the three genotypes (data not shown).(C4/2; C15/2) as well as homozygous (C4/C4; C15/C15)
Western blot analysis of brain tissue of terminally illmice presented with scrapie-like symptoms similar to
C4/C4 and C15/2 mice revealed only traces of protease-those of wild-type mice, including ataxia and kyphosis,
resistant PrP (Figure 1B). This finding could come aboutexcept that both lines developed front leg paresis in the
either because less PrPSc accumulated or becauselate stages of the disease, while the hind legs seemed
PrPScD32±93 was less resistant to proteinase K diges-less affected.
tion. In order to compare the level of PrPScD32±93 withBrain sections of six terminally ill animals (two of each
that of full-length PrPSc without making use of proteaseC4/C4, C15/C15, and C4/2) were examined for patho-
digestion, we made use of the finding that full-lengthlogical changes. Neither spongiosis nor gliosis was evi-
PrPScand its protease-resistant moiety, PrP27±30, whichdent in the thalamus (Figures 3D and 3E), brainstem
lacks 60 amino-terminal residues, are precipitated by(Figures 3K and 3L), or hippocampus (data not shown)
sodium phosphotungstate (NaPTA) with the same effi-of transgenic mice, while strong spongiosis and gliosis
ciency, while PrPC is essentially not precipitated (Safarwere found in terminally ill wild-type mice and transgenic
mice overexpressing full-length PrP (tga20/tga20) or PrP et al., 1998). We added 1.8 mg total protein from brains
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Table 1. Response of Mice with Various PrP Genotypes to Intracerebral Inoculation with Mouse Scrapie Prions
PrP Days to Symptoms Days to Terminal
Inoculum Recipient Mouse Line [Genotype] Gene copiesa Levelb 6 SD (n) Disease 6 SD (n)
RML C4/2 [Prnpo/o, tg(PrPD32±93/2)] 25 4c 232 6 14 (4) 257 6 7 (4)
RML C4/C4 [Prnpo/o, tg(PrPD32±93/PrPD32±93)] n.d. (50) 4d 219 6 20 (6) 232 6 21 (6)
RML C4h C4/C4 [Prnpo/o, tg(PrPD32±93/PrPD32±93)] n.d. (50) 4d 232 6 20 (6) 244 6 16 (6)
RML C15/2 [Prnpo/o, tg(PrPD32±93/2)] 25 3c 313 6 23 (5) 371 6 15 (3)
RML C15/C15 [Prnpo/o, tg(PrPD32±93/PrPD32±93)] n.d. (50) 3.8d 214 6 41 (3) 239 6 45 (3)
RML wild type; C57BL/6 3 129/Sv [Prnp1/1] 2e 1e 158 6 11 (31)f 171 6 11 (31)f
RML PrP hemizygous [Prnp1/o] 1e 0.5e 290 6 33 (19)g 415 6 30 (15)g
a Relative to wild type; determined by quantitative PCR. In parentheses, extrapolated from hemizygous animals.
b Relative to wild type; determined by densitometric analysis of Western blots.
c PrP was detected with a polyclonal antibody R340 (Brandner et al., 1996), and signals were quantified relative to those of wild-type mice
(without internal control).
d PrP was detected with a monoclonal antibody 6H4 (Prionics AG, Switzerland), and signals were quantified in comparison to those of wild-
type mice, with APP as internal control (see Figure 1A).
e By definition.
f (BuÈ eler et al., 1993).
g (BuÈ eler et al., 1994).
h RML C4 prions are from RML-infected terminally ill C4/C4 mice.
n, Number of animals; n.d., not done.
of terminally ill, RML-infected wild-type or C4/C4 mice amounts of PrP in the pellets both before and after di-
gestion with proteinase K. Before digestion, there wasto a 10% homogenate of Prnpo/o brain, carried out the
phosphotungstate precipitation, and compared the about 50 times less NaPTA-precipitable PrPD32±93 than
Figure 2. Distribution of Total PrP and PrPSc
in Coronal Brain Sections of Wild-Type and
Transgenic Mice
(A) Immunostaining of PrP cerebrum (upper
row) and brainstem±cerebellum of uninfected
mice (lower row). Truncated PrP (third col-
umn) is expressed in a similar pattern as full-
length PrP in wild-type brain.
(B) Histoblots of cerebrum (upper two rows)
and cerebellum with brainstem (lower two
rows) of terminally ill, RML-infected mice.
Blots were treated with 100 mg/ml proteinase
K (100) or not treated (0). While PrPSc is pres-
ent throughout the cerebrum, cerebellum,
and brainstem of RML-infected, wild-type
mice (first column), it is found mainly in the
thalamus and brainstem of terminally ill
tga20/tga20 mice (second column) and C4/
C4 mice (third column) inoculated with RML
scrapie. Brains of tga20/tga20 mice (fourth
column) infected with 1% brain homogenate
from terminally ill C4/C4 mice (which had
originally been infected with RML inoculum)
exhibit proteinase K±resistant PrP immuno-
staining indistinguishable from that of RML-
infected tga20/tga20 brains (second column).
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Figure 3. Brain Sections of Terminally Ill Mice
Expressing Wild-Type or Amino-Proximally
Truncated PrP
Coronal sections of thalamus (A±G) and
brainstem (H±N) were stained with hematoxy-
lin±eosin (HE) or immunostained for glial fibril-
lary acidic protein (GFAP). At the left of each
row, the inoculum and the line of the experi-
mental animal are indicated. RML-infected,
wild-type mice (A and H), tga20/tga20 mice
(overexpressing wild-type PrP; [B and I]), and
tgd12/tgd12 (overexpressing PrPD32±80 [Fi-
scher et al., 1996]; [C and J]) show spongiosis
(HE) and pronounced astrocytosis (GFAP) in
both brainstem and thalamus. RML-infected
C4/C4 (D and K) or C15/C15 (E and L) mice
that overexpress PrPD32±93 and are devoid
of all octarepeats show no evident histopa-
thology. Some perivascular shrinkage in the
brainstem of C15/C15 mice (L) can be distin-
guished from spongiosis at higher magnifica-
tion (data not shown). C4/C4 mice inoculated
with prions passaged once through C4/C4
mice exhibited no spongiosis and only mod-
erate gliosis in the thalamus (F), but mild
spongiosis and reactive astrocytic gliosis
were evident in the brainstem (M). Uninfected
wild-type mice (G and N) served as negative
controls.
full-length PrP (Figure 1C), and after digestion, about 30 PrP found by Western analysis of homogenate superna-
tants. Examination of the low-speed pellets resultingtimes less (Figure 1D). This means that the proportion of
digestible PrP is about the same for the wild type and the from the centrifugation of the initial brain homogenates
(which are usually discarded) excluded the possibilityC4/C4 sample (Figures 1C and 1D cannot be compared
directly because the blots resulted from different experi- that truncated PrPSc was segregated into that fraction,
confirming the previous conclusions. Most likely, thements). Thus, we conclude that the low level of protease-
resistant PrPD32±93 reflects a low rate of accumulation signal intensities in the histoblot are not linear with the
amount of PrPSc present.and not an increased susceptibility to proteolysis.
The distribution of protease-resistant PrPD32±93 as
judged by (nonquantitative) histoblot analysis was simi-
lar to that in terminally ill transgenic mice overexpressing Prion Titers in Scrapie-Infected PrP Knockout
Mice Expressing PrPD32±93full-length PrP (tga20/tga20) (Figure 2B). However, the
intensity of staining of wild-type and mutant samples Prion titers in spleen and brain of infected animals were
determined by inoculating homogenates i.c. into tga20/did not reflect the 30-fold lower levels of the truncated
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Figure 4. Sections of the Cervical Spinal
Cord Wild-Type and Transgenic Mice
(A) Coronal sections showing the Rexed layer
IX of the cervical spinal cord level C4 of termi-
nally ill scrapie-infected Prnp1/1, tga20/
tga20, and C4/C4 mice. Motor neurons were
identified by their large size, pale nuclei, and
content of microtubule-associated protein 2
(MAP-2), as determined by immunohisto-
chemistry. The pathological changes in C4/
C4 mice inoculated with either RML or RML
C4 prions (prions derived from RML-inocu-
lated C4/C4 mice) were indistinguishable
from RML-infected wild-type and tga20/
tga20 mice as judged by immunostaining for
GFAP. There is no gliosis or loss of motor
neurons in uninfected C4/C4 mice compared
to wild-type controls.
(B) Graphic representation of the number of
motor neurons in the Rexed layers VIII and IX
in the ventral spinal cord from levels C4±C8
of RML-infected Prnp1/1, C4/C4, and tga20/
tga20 mice. The statistical significance of mo-
tor neuron loss in infected and uninfected ani-
mals was analyzed separately for each cer-
vical spinal cord segment by parametric
statistics (two-tailed t test). The number of
motor neurons in the set of infected mice of
all genotypes is reduced by about 10%±25%
compared with the set of uninfected mice of
the same age. Differences between infected
mice of the various genotypes are not statisti-
cally significant. **p , 0.0005, *p , 0.025.
tga20 indicator mice (Table 2). A mouse homozygous RML-inoculated C4/C4 compared to wild-type mice,
they are the same in spinal cord.for the PrnpD32±93 cluster (C4/C4), sacrificed 4 months
after inoculation, had a titer of about 2 log LD50 U/ml
PrPD32±93-Expressing Brain Grafts Propagate Prions10% brain homogenate but no significant infectivity in
and Remain Devoid of Scrapie-like Pathologythe spleen (Table 2). After 8 months, when clinical symp-
To further investigate pathogenesis in brain tissue ex-toms were apparent, the titer in the pooled brain homog-
pressing PrPD32±93, embryonal neuroectodermal tis-enates of 2 C4/C4 mice was about 7 log LD50 U/ml 10%
sue from C4/C4 mice was grafted (Isenmann et al., 1996)homogenate and in the spleen infectivity was at border-
into the caudoputamen of adult Prnpo/o mice and inocu-line detectability (about 2.5 log LD50 U/ml 10% homoge-
lated i.c. with RML prions (Figure 5). As reported earlier,nate). Similarly low titers were also found in brain and
tga20/tga20 grafts (6/6) showed strong neuronal loss,spleen of a terminally ill C15/2 mouse analyzed (Table
spongiosis, and gliosis by 200 days after inoculation2). No significant infectivity could be detected in the
with mouse prions (Brandner et al., 1996), while C4/C4spleen of C15/C15 mice 4 weeks after i.c. inoculation,
grafts (10/10), 268 days after inoculation, showed noa time at which prion levels in the spleen reached close
pathological changes, although they differentiated intoto maximal value in infected wild-type mice (BuÈ eler et
neuronal and glial tissue, as evidenced by synaptophy-al., 1993). Thus, 4 weeks after i.c. inoculation, spleens
sin and GFAP staining, and accumulated PrPSc (Figureof such transgenic mice contained at least 105 times
5). These findings confirm the results described above,less prions than those of wild-type mice (5.2 log LD50 namely that no pathological changes could be observed
U/ml 10% homogenate), showing that truncation also by light microscopy in brain tissue from scrapie-infected
dramatically affects prion accumulation in the spleen. mice expressing PrP devoid of the octarepeat region.
Transmission of 30 ml 1% homogenate of cervical and Four such infected C4/C4 grafts were recovered, ho-
thoracic spinal cord segments of two terminally ill C4/ mogenized, and each homogenate inoculated into four
C4 mice into the brains of indicator mice caused terminal tga20/tga20 indicator mice. In all cases (16/16), terminal
disease after 63 6 2 days (4/4) and 69 6 1 days (4/4), scrapie resulted after 102 6 16 days. Two RML-infected
respectively. Similar incubation times were found after tga20/tga20 graft homogenates caused terminal dis-
transmission of cervical and thoracic spinal cord seg- ease in indicator mice (8/8) after 66 6 4 days, reflecting
ments of two terminally ill wild-type mice, namely 69 6 the higher titers attained in brains of tga20/tga20 mice
1 (3/3) and 69 6 0 days (4/4), respectively. Thus, although as compared to those of C4/C4 mice. Because no in-
fectivity was found in two PrP-deficient grafts 226 daysinfectivity titers are about 30 times lower in brains of
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Table 2. Infectivity in Organs of Prion-Inoculated Micea
Scrapie-Ill Recipients n/no (days
p.i. 6 SD) Titer b
Inoculum Inoculated Mouse Line [Genotype] Months p.i. Dilution Spleen Brain Spleen Brain
Preclinical Stage
RML C4/2 [Prnpo/o, tg(PrPD32±93/2)] 2 1021 0/4 (.200) 4/4 (112 6 14) ,1 2.2
RML C4/C4 [Prnpo/o, tg(PrPD32±93/PrPD32±93)] 4 1021 1/8 (113) 10/10 (115 6 16) ,1.5 1.9
RML C15/C15 [Prnpo/o, tg(PrPD32±93/PrPD32±93)] 1 1021 0/4 (.200) n.d. ,1 n.d.
RML wild type [Prnp1/1] (2 spleens pooled) 1 1021 3/3 (75 6 1) n.d. 5.2c n.d.
1023 4/4 (91 6 10)
1024 1/4 (94)
1025 0/5 (.200)
Terminal stage
RML C4/C4 [Prnpo/o, tg(PrPD32±93/PrPD32±93)] 8 1021 2/4 (111 6 6) 4/4 (68 6 2) ,2.5 7.0c
(2 brains, 2 spleens pooled) 1023 4/4 (80 6 5)
1024 4/4 (90 6 6)
1025 4/4 (114 6 12)
1026 0/4 (.130)
1027 0/4 (.130)
RML C4d C4/C4 [Prnpo/o, tg(PrPD32±93/PrPD32±93)] 8 1021 n.d. 4/4 (68 6 1) n.d. 6.7c
(2 brains pooled) 1023 4/4 (88 6 6)
1024 4/4 (100 6 9)
1025 2/4 (102 6 11)
1026 1/5 (97)
1027 0/4 (.130)
RML C15/2[Prnpo/o, tg(PrPD32±93/2)] 10 1021 2/4 (113 6 6) 3/3 (69 6 2) ,2.5 7.3
1022 0/2 (.200) 4/4 (73 6 3)
1023 4/4 (84 6 5)
RML wild type [Prnp1/1] (2 brains pooled) 5 1021 n.d. 3/3 (65 6 10) n.d. 8.2c
1023 4/4 (65 6 5)
1025 4/4 (88 6 3)
1026 3/3 (92 6 15)
1027 1/4 (129)
1028 0/4 (.200)
a Unless stated otherwise, one organ was assayed. Of the indicated dilution of a 10% tissue homogenate 30 ml was injected i.c. into tga20/
tga20 mice. Animals were observed for 200 days. n/no, number of animals acquiring scrapie/number of animals inoculated. n.d., not done.
b Titers (log LD50 U/ml of 10% homogenate) were determined by the incubation time method (Prusiner et al., 1982) using the standard curve
for tga20/tga20 (Brandner et al., 1996). Limit of detection: z1 log LD50 U/ml 10% homogenate.
c Titer calculated by endpoint titration (Reed and Muench, 1938).
d RML C4 prions are from RML-infected terminally ill C4/C4 mice.
after RML inoculation, assayed in four mice each (0/8), in contrast to RML-infected C4/C4 or C15/C15 mice,
where no pathology was detected (Figures 3D and 3Kit is unlikely that infectivity was due to residual inoculum.
or 3E and 3L, respectively). The distribution of PrPSc in
brains of C4/C4 mice, as judged by histoblotting, wasProperties of Prions from RML-Infected Transgenic
similar whether inoculation was with RML prions or withMice Expressing PrPD32±93 Passaged through
prions derived from RML-infected C4/C4 mice (data notMice Expressing the Same Transgene
shown). Inoculation of mice expressing wild-type PrPPrions from a donor whose PrP sequence differs from
(tga20/tga20) with 1% brain homogenates from RML- orthat of the recipient may cause disease after a much
RML-C4-infected, sick mice caused scrapie after similarlonger incubation time than prions from a donor with the
incubation times, namely 68 days (Table 2).same sequence, a phenomenon designated as ªprion
Estimated titers in brains of C4/C4 mice inoculatedtransmission barrierº and considered to be equivalent
with RML or C4/C4-passaged RML were about 7 andto the naturally occurring ªspecies barriersº (Scott et
6.7 LD50 U/ml 10% homogenate, respectively. Thus, theal., 1989). Because the difference between PrPD32±93
moderate pathological changes in the brains of C4/C4and wild-type PrP might cause a prion transmission
mice inoculated with C4/C4-passaged RML were notbarrier, brain homogenates pooled from two RML-
associated with a higher prion titer than that in RML-infected, sick C4/C4 mice were inoculated into C4/C4
inoculated C4/C4 mice, which had no discernible brainmice to overcome such a conjectural barrier. However,
pathology (Table 2). In this regard, passaging RML onceall inoculated mice (6/6) succumbed to scrapie after
through C4/C4 mice did not change its properties.244 6 16 days, that is, after a delay similar to that re-
sulting after RML infection, namely 232 6 21 (Table 1).
Thus, RML passaged once through C4/C4 mice did not
Discussionresult in reduced incubation time; however, it did give
rise to moderate spongiosis in the brainstem (Figure 3M)
and mild reactive astrocytosis in thalamus and brain- The N-terminal half of PrP contains a conserved region
of tandem repeats of an eight amino acid sequencestem of three C4/C4 mice analyzed (Figures 3F and 3M),
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Figure 5. Immunohistochemistry and Histoblots of RML-Infected and Uninfected Neuroectodermal Grafts Derived from tga20/tga20 and C4/
C4 Embryos in Prnpo/o Mouse Brain
Engrafted mice were prepared and inoculated as described in the Experimental Procedures. Deparaffinized brain sections were stained with
hematoxylin±eosin (HE) or antibodies to GFAP. There was significant spongiosis and astrogliosis in tga20/tga20 grafts (200 days after
inoculation; left) but not in C4/C4 grafts (268 days after inoculation; middle) or in uninfected tga20/tga20 grafts (286 days after transplantation,
right). Synaptophysin immunoreactivity (SYN) in C4/C4 grafts documents full differentiation into neuronal tissue and remained unchanged in
infected C4/C4 grafts. Synaptophysin was reduced in infected tga20/tga20 grafts, indicating neuronal damage. PrP (PRP) immunoreactivity
reveals prominent punctate deposits in RML-infected tga20/tga20 grafts but only few deposits in RML-infected C4/C4 and none in uninfected
tga20/tga20 grafts. PrP was detected by polyclonal antisera R340 and visualized using the Tyramide Signal Amplification kit (NEN, Life Science,
Boston). The bottom row shows histoblots of the three groups with (1PK) or without (2PK) proteinase K digestion. Proteinase K±treated
histoblots display intense PrP immunostaining in both infected grafts but not in uninfected tga20/tga20 grafts (arrows).
(octarepeats) with affinity for copper ions (Hornshaw et mice accumulate high levels of infectivity and PrPSc by
20±24 weeks and yet remain free of symptoms for 30al., 1995; Viles et al., 1999). Amplification of the repeat
number beyond the usual five has been found in associa- weeks thereafter (BuÈ eler et al., 1994). The prion titers in
the brains of mice expressing PrP devoid of all fivetion with human familial prion diseases (Collinge, 1997),
and the number of repeats appears to determine the octarepeats (PrPD32±93) were lower at all stages of the
disease; in terminally sick mice, infectivity was abouttype of cerebellar amyloid deposits (Vital et al., 1998).
In this paper, we asked the question of whether the 10±30 times and protease-resistant and NaPTA-precipi-
table PrP about 30±50 times lower than in their wild-typeoctarepeat region of PrP is essential for sustaining prion
replication and scrapie disease. We therefore intro- counterparts. Because the transgenic mice expressed
about four times more PrP than wild-type mice andduced into Prnpo/o mice PrP transgenes from which the
segment comprising codons 32±93 had been deleted. showed the same expression pattern, we conclude that
the long incubation times and low prion and PrPSc levelsThe resulting mature protein contained the first nine
amino acids (retained, albeit unnecessarily as later are the consequence of the deletion. Considering that
the scrapie form of truncated PrP has the same degreeemerged [Supattapone et al., 1999], to ensure correct
posttranslational processing) and was devoid of all octa- of resistance to protease as that of full-length PrP, it
seems unlikely that the low prion and PrPSc levels arerepeats. Two lines of mice homozyous for the transgene
cluster, C4/C4 and C15/C15, expressed the truncated the result of more rapid turnover; rather, we believe
that they are the consequence of a decrease in thePrP at about four times wild-type level and with the
same overall distribution pattern as in wild type. Mice conversion rate of the truncated PrP.
Strikingly, we were unable to discern histopathologi-hemizygous or homozygous for the cluster were chal-
lenged with mouse prions. All animals succumbed to cal lesions in brain and brainstem of terminally ill
PrPD32±93 animals at the level of light microscopy, notscrapie-like disease, showing that the truncated PrP
was competent in this regard. Interestingly, the animals even the astrogliosis that so far has been found in all
murine scrapie disease. On the other hand, infectivity,showed front leg paresis rather than the usual hind leg
symptoms. Incubation times to first symptoms (31±45 gliosis, and loss of motor neurons in the cervical seg-
ment of the spinal cord were similar in C4/C4 and wild-weeks) and to terminal disease (34±53 weeks) were
longer than for wild-type controls (22.5 and 24.5 weeks, type mice or in transgenic mice overexpressing full-
length PrP (tga20/tga20).respectively), albeit shorter than for hemizygous Prnpo/1
mice (41 and 60 weeks, respectively) (BuÈ eler et al., 1994; It is remarkable that lethal disease developed at such
low overall levels of PrPSc in the brain, raising once moreManson et al., 1994). While, in wild-type mice, accumula-
tion of prions and PrPSc is followed within weeks by the question as to whether the protease-resistant form
of PrP plays a direct pathogenetic role in brain. Tga20/clinical symptoms and death, hemizygous PrP knockout
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tga20 mice overexpressing full-length PrP 10-fold have 88). We can currently not determine which of these dif-
a vastly reduced incubation time (about 65 days) as ferences or combination of differences is critical.
compared to wild-type mice with a similar genetic back- While PrP devoid of the octarepeats sustains scrapie-
ground (about 170 days), and at preterminal disease like disease in response to scrapie prions, the course
have at least equal prion titers as their wild-type counter- and presentation of disease are profoundly modified. In
parts but lower levels of PrPSc (Fischer et al., 1996). particular, it is striking that animals die of a neurological
Previous reports have shown that extracellular PrPSc disease without the histopathological changes in the
does not give rise to pathological changes in brains of brain typical for mouse scrapie. It is possible that the
Prnpo/o mice (Brandner et al., 1996) and that PrPSc was mice suffer from a disease that is confined to the spinal
not detectable in lethal scrapie-like disease in mice over- cord or to some restricted ªclinical target areasº in
expressing mutant PrP transgenes (Telling et al., 1996), which, it was suggested, scrapie agent must replicate
in some wild-type mice inoculated with BSE prions (Las- for lethal disease to develop (Kimberlin et al., 1987a).
mezas et al., 1997; Manson et al., 1999) or in mice with It is, however, also possible that the critical events in
a P101L mutation in their PrP genes (Manson et al., pathogenesis occur at the submicroscopic or molecular
1999). It is, however, not permissible to conclude from level and that vacuolation, astrocytosis, and extensive
data of this kind that PrPSc as such is not infectious, neuronal cell death are late features not essential for
because a 1000-fold reduction of the level of PrPSc found clinical disease. These conclusions are complementary
in wild-type, scrapie-ill mice would render it undetect- to the ones drawn in the case of scrapie-infected
able by commonly used methods, while a 1000-fold Prnpo/1 mice, where strong astrocytosis, PrPSc deposi-
lower titer would still amount to .105 LD50 U/ml 10% tion and high prion titers were found to be compatible
brain homogenate. with absence of clinical disease for over 30 weeks
ªRML C4º prions resulting from RML-infected mice (BuÈ eler et al., 1994). The molecular basis of scrapie
expressing PrPD32±93 gave similar incubation times as pathogenesis remains as elusive as ever.
RML prions when they were inoculated into mice ex-
pressing the same transgene and efficiently transmitted Experimental Procedures
disease to mice expressing full-length PrP; by these
Generation, Identification, and Maintenancecriteria, there is no evidence for a ªprion transmission
of Transgenic Micebarrierº (Scott et al., 1989, 1993; Prusiner et al., 1990).
The PrPD32±93 reading frame was introduced into the ªhalf-geno-However, RML C4 prions engendered moderate astro-
micº PrP vector (Fischer et al., 1996) as described (Shmerling et al.,cytosis in the brainstem of C4/C4 mice, which was not
1998). Fertilized oocytes from Prnpo/o mice were injected to generatefound after challenge with RML prions, possibly indicat-
the C4 line (Brinster et al., 1985; Wilmut et al., 1991). Microinjection of
ing some difference in their properties. Because the the construct into oocytes resulting from a cross between Prnpo/o
Chandler isolate-derived RML is a strain mixture (Kim- and wild-type C57BL/6 mice yielded the C15 founder. Transgene-
berlin et al., 1987b), it is not clear whether such a change positive founders were mated to Prnpo/o mice and two transgenic
would reflect selection of a minority population or modi- lines designated C4/2 and C15/2 were established from F1 progeny
on a Prnpo/o mixed background C57BL/6 3 129/Sv (BuÈ eler et al.,fication or de novo generation of a strain.
1992). Further breeding yielded the homozygous lines C4/C4 andIn contrast to our PrPD32±93 lines described here, a
C15/C15. Transgene copy numbers were estimated relative toline of transgenic mice expressing PrP with deletions of
Prnpo/o alleles by quantitative PCR as detailed earlier (Shmerling etamino acids 23±88 at a similar level as ours were resis-
al., 1998).tant to RML prions when on a PrP knockout background
(Supattapone et al., 1999). Surprisingly, when on a
Western Blot Analysis
Prnpo/1 background, the same truncated PrP appeared Brain homogenates (10%, w/v) were prepared in PBS, 0.5% NP40,
to be permissive for mouse RML prions, as evidenced 0.5% sodium deoxycholate by passing brains through 18 gauge and
by the accumulation of truncated PrPSc. The authors 22 gauge needles. After centrifugation at 1500 3 g for 10 min,
suggest that full-length PrP acts in trans, possibly by a supernatants were adjusted to 8 mg/ml of total protein. Where indi-
direct interaction with the truncated PrP. However, it is cated, aliquots were digested with 20 mg/ml proteinase K for 30 min
at 378C, adjusted to 2 mM PMSF, and boiled in SDS-PAGE loadingalso possible that the high levels of prions and PrPSc
buffer with b-mercaptoethanol. The samples (40 mg or 80 mg of totalaccumulating in mice with a Prnpo/1 background (BuÈ eler
protein in Figure 1A and Figure 1B, respectively) were electropho-et al., 1994) entrain conversion of the truncated PrP, a
resed through 16% SDS-polyacrylamide gels (NOVEX, San Diego)process that may be occurring at only an undetectable
and transferred to PVDF membranes. PrP was detected with mono-level on a Prnpo/o background, where the inoculum dis-
clonal antibody 6H4 (1:10.000, Prionics AG, Switzerland [Korth et al.,
appears from the brain almost completely within days 1997]) and Alzheimer precursor protein (APP) with the monoclonal
(BuÈ eler et al., 1993). antibody 22C11 (1:5000, Boehringer Mannheim, Germany). Blots
There are three differences between the transgenic were incubated with horseradish peroxidase±conjugated anti-
lines we describe and these so-called Tg(MHM2,D23± mouse IgG1 antibodies (1:5000, ZYMED, San Francisco), developed
88) Prnpo/o mice that could account for their different using the enhanced chemiluminescence kit SuperSignal West Pico
(Pierce, Rockford), and exposed to BIOMAX MR-1 film (Kodak,susceptibility to scrapie. First, our PrPD32±93 construct
Rochester). An appropriate film exposure was scanned with a laserpreserves the nine amino-terminal residues (23±31) of
densitometer (Molecular Dynamics) and quantified using Im-the mature protein that are lacking in the product en-
ageQuant software.coded by the MHM2 PrP(D23±88) ORF. This domain
comprises a highly conserved motif (KKRPKP) and has
Phosphotungstate Precipitationbeen implicated in a dominant-negative effect on PrPSc Brain homogenates (10% w/v, in PBS) from Prnpo/o, uninfected C4/
formation in cell culture (Zulianello et al., 2000). Second, C4, RML-infected, terminally ill wild-type, as well as C4/C4 mice
the chimeric MHM2 PrP(D23±88) contains two amino were prepared as above and centrifuged at 1500 3 g for 10 min.
acid substitutions in the ªhamster domainº H, in posi- An aliquot of each wild-type or C4/C4 supernatant (1.8 mg total
tions 108 and 111. Third, five residues (89±93) that are protein) was mixed with Prnpo/o supernatant to give a final volume
of 0.5 ml and NaPTA precipitation of the abnormal form of PrP wasabsent in our PrPD32±93 are present in MHM2 PrP(D23±
Prion Protein Devoid of Octapeptide Repeat
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performed by the method of Safar et al. (1998), as modified by J. antibody against microtubule-associated protein 2 (MAP-2, 1:1000,
Boehringer Mannheim, Germany). Motor neurons were identified byWadsworth (personal communication). For Figure 1C, final pellets
were resuspended in 32 ml 8 M urea sample buffer (SDS-PAGE their location in the ventral horn of the spinal cord (Rexed laminae
VIII and IX) and by MAP-2 staining. Cells were counted in the ventralloading buffer, 4% b-mercaptoethanol, 20 mM methylamine) and
boiled for 15 min. Aliquots (22 ml) or fractions thereof as indicated horn of the cervical and lumbar spinal cord at 4003 magnification
in 15 focal planes at 100 mm intervals, as described (Clarke andwere analyzed by Western blotting as described above. For Figure
1D, pellets were resuspended in 15.2 ml PBS, 0.1% Sarkosyl and Oppenheim, 1995).
digested with 50 mg/ml proteinase K for 1 hr at 378C. PMSF was
added to 2 mM and loading buffer with b-mercaptoethanol was Acknowledgments
added to a final volume of 32 ml. After boiling, aliquots of 22 ml or
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